HDAC4/MybL1/YAP novel signaling axis is required for pancreatic cancer metastasis to the liver

By afschroeder • November 25, 2025

Edderkaoui M, Elmadbouh OHM, Lim A, Ou Y, Hauptschein D, Guha A, Darwish A, Calsavara VF, Murali R, Bhowmick N, Osipov A, Mathison AJ, Urrutia R, Wang Q, Pandol SJ. HDAC4/MybL1/YAP novel signaling axis is required for pancreatic cancer metastasis to the liver. Int J Biol Sci. 2025 Oct 24;21(15):6907-6925. doi: 10.7150/ijbs.102132. PMID: 41281751; PMCID: PMC12631223.

Tags: Cedars Sinai DoM, Digestive Diseases, Hematology/Oncology, Publications

Related Posts

Are Urologists and/or Radiation Oncologists Biased when Reporting of Advantages and Disadvantages of Surgery versus Radiation in Consultations for Early-Stage Prostate Cancer?

Friedrich NA, Luu M, Gale R, Chaplin A, Polineni R, Shiang A, Shin D, Freedland SJ, Spiegel B, Ballas LK, Kokorowski P, Daskivich TJ. Are[...]

Charting the translational pathway: ISSCR best practices for the development of PSC-derived therapies

Barry J, Abranches E, Baptista RP, Barry C, Brandsten C, Bruce K, Carpenter MK, Cavagnaro J, Collins L, Csaszar E, Dashnau J, de Villa D,[...]

Diagnostic Performance of F-18 Flurpiridaz in Women: A Sub-study of the Aurora Phase 3 Trial

Horgan SJ, Heller GV, Maddahi J, Bateman TM, Bax JJ, Beanlands RSB, Berman DS, Garcia EV, Somer E, Tamaki N, Thompson D, Udelson JE. Diagnostic[...]